科学界神雕侠侣，“吵”出一款世界级新药

Core Viewpoint - The article highlights the collaborative journey of two prominent scientists, Li Wenhui and Sui Jianhua, who have made significant contributions to the field of virology and antibody engineering, culminating in the development of the first monoclonal antibody drug for viral hepatitis, Lebevetab [1][2][6]. Group 1: Background and Education - Li Wenhui and Sui Jianhua met at Lanzhou University over 30 years ago and have since pursued parallel academic paths, including postdoctoral research at Harvard University [2][3]. - Their scientific collaboration began shortly after their marriage, leading to groundbreaking discoveries in the fields of SARS and hepatitis B [1][4]. Group 2: Research Contributions - Li Wenhui was the first to identify the receptor for the SARS virus, while Sui Jianhua developed the first human-derived antibody against SARS [3][6]. - Sui Jianhua discovered a broad-spectrum neutralizing antibody for the H1N1 influenza virus, which has implications for future antiviral treatments and vaccine development [5][6]. - In 2012, Li Wenhui identified the hepatitis B virus receptor, a significant breakthrough after decades of research [6][8]. Group 3: Company Formation and Drug Development - In 2015, the couple co-founded Huahui Anjian, a biopharmaceutical company aimed at developing innovative treatments for liver diseases [11][12]. - The company focuses on transforming scientific discoveries into practical applications, with Li Wenhui handling basic scientific research and Sui Jianhua managing operations and clinical trials [11][12]. Group 4: Personal Dynamics and Work Ethic - The couple is known for their intense debates on scientific topics, which they view as a means of intellectual growth rather than conflict [11][13]. - Their complementary skills—Li Wenhui's critical thinking and Sui Jianhua's practical application—allow for seamless collaboration in their research endeavors [8][11].